NCT03044873View on ClinicalTrials.gov

Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

March 14, 2017

Study Completion Date

March 27, 2017

Conditions
Autoimmune DiseasesInflammatory Diseases
Interventions
DRUG

BMS-986165

Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.

DRUG

Rosuvastatin

Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.

Trial Locations (1)

78744

PPD Phase I Clinic, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03044873 - Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin | Biotech Hunter | Biotech Hunter